地塞米松玻璃体腔植入剂异位于前房一例_Chinese Journal of Ocular Fundus Diseases

Authors：

吴頔 , 任新军 ,  李筱荣

天津医科大学眼科医院、眼视光学院、眼科研究所，天津市视网膜功能与疾病重点实验室 300384;

Corresponding author：

李筱荣, Email: xiaorli@163.com

Keywords：

地塞米松; 迟效制剂; 病例报告; 异位; 前房

DOI：

10.3760/cma.j.issn.1005-1015.2019.06.019

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 吴頔, 任新军, 李筱荣. 地塞米松玻璃体腔植入剂异位于前房一例. Chinese Journal of Ocular Fundus Diseases, 2019, 35(6): 608-609. doi: 10.3760/cma.j.issn.1005-1015.2019.06.019 Copy

1.	Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema[J]. Retina, 2009, 29(1): 46-51. DOI: 10.1097/IAE.0b013e318188c814.
2.	Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration:risk factors, complications, and management strategies[J]. Ophthalmology, 2014, 121(1): 67-71. DOI: 10.1016/j.ophtha.2013.06.033.
3.	Rezar-Dreindl S, Eibenberger K, Pollreisz A, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion[J]. Acta Ophthalmol, 2017, 95(2): 119-127. DOI: 10.1111/aos.13152.
4.	Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study[J]. Am J Ophthalmol, 2015, 160(2): 313-321. DOI: 10.1016/j.ajo.2015.04.025.
5.	黎晓新, 王宁利, 梁小玲, 等. 地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性:随机、假注射对照、多中心研究[J]. 中华眼底病杂志, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.Li XX, Wang NL, Liang XL, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusionin Chinese patients: randomized,sham-controlled,multicenter study[J]. Chin J Ocul Fundus Dis, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.
6.	Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(R) implant[J]. J Ophthalmic Inflamm Infect, 2012, 2(1): 1-5. DOI: 10.1007/s12348-011-0042-x.
7.	Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravitreal implant (Ozurdex^®) migrated into the anterior chamber[J]. Int Ophthalmol, 2012, 32(6): 583-584. DOI: 10.1007/s10792-012-9604-7.
8.	Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex^®)[J]. Graefe's Arch Clin Exp Ophthalmol, 2012, 250(11): 1703-1704. DOI: 10.1007/s00417-011-1802-x.
9.	Gullapalli VK, DiLoreto DA. Migration of intravitreal dexamethasone implant to anterior chamber[J]. Retin Cases Brief Rep, 2013, 7(1): 111-113. DOI: 10.1097/ICB.0b013e31826f08b0.
10.	Rahimy E, Pitcher Ⅲ JD, Abbey AM, et al. No-touch removal of anterior segment-migrated dexamethasone implant[J]. Retina, 2015, 35(11): 2414-2416. DOI: 10.1097/IAE.0000000000000753.

1. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema[J]. Retina, 2009, 29(1): 46-51. DOI: 10.1097/IAE.0b013e318188c814.
2. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration:risk factors, complications, and management strategies[J]. Ophthalmology, 2014, 121(1): 67-71. DOI: 10.1016/j.ophtha.2013.06.033.
3. Rezar-Dreindl S, Eibenberger K, Pollreisz A, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion[J]. Acta Ophthalmol, 2017, 95(2): 119-127. DOI: 10.1111/aos.13152.
4. Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study[J]. Am J Ophthalmol, 2015, 160(2): 313-321. DOI: 10.1016/j.ajo.2015.04.025.
5. 黎晓新, 王宁利, 梁小玲, 等. 地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性:随机、假注射对照、多中心研究[J]. 中华眼底病杂志, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.Li XX, Wang NL, Liang XL, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusionin Chinese patients: randomized,sham-controlled,multicenter study[J]. Chin J Ocul Fundus Dis, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.
6. Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(R) implant[J]. J Ophthalmic Inflamm Infect, 2012, 2(1): 1-5. DOI: 10.1007/s12348-011-0042-x.
7. Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravitreal implant (Ozurdex^®) migrated into the anterior chamber[J]. Int Ophthalmol, 2012, 32(6): 583-584. DOI: 10.1007/s10792-012-9604-7.
8. Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex^®)[J]. Graefe's Arch Clin Exp Ophthalmol, 2012, 250(11): 1703-1704. DOI: 10.1007/s00417-011-1802-x.
9. Gullapalli VK, DiLoreto DA. Migration of intravitreal dexamethasone implant to anterior chamber[J]. Retin Cases Brief Rep, 2013, 7(1): 111-113. DOI: 10.1097/ICB.0b013e31826f08b0.
10. Rahimy E, Pitcher Ⅲ JD, Abbey AM, et al. No-touch removal of anterior segment-migrated dexamethasone implant[J]. Retina, 2015, 35(11): 2414-2416. DOI: 10.1097/IAE.0000000000000753.

Chinese Journal of Ocular Fundus Diseases

地塞米松玻璃体腔植入剂异位于前房一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content